1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Pacira's Exparel For Nerve Block Use Gets Day-Plus US FDA Panel Review

 
• By Brenda Sandburg

Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.

FDA entrance sign 2016

Three years after receiving a "complete response letter" for its Exparel (bupivacaine liposome injectable suspension) supplemental new drug application for use as a nerve block, Pacira Pharmaceuticals Inc. will be presenting new data to a US FDA advisory committee.

The agency announced in a Federal Register notice to be published Jan. 11 that the Anesthetic and Analgesic Drug Products...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 
• By Bridget Silverman

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.